Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Vasculitis and Thrombophlebitis

  • Author: Nadia Jennifer Chiara Luca, MD; Chief Editor: Lawrence K Jung, MD  more...
 
Updated: Jun 30, 2015
 

Background

Vasculitis is defined as inflammation of blood vessels. It may result in vessel wall thickening, stenosis, and occlusion with subsequent ischemia. Necrotizing inflammation can completely destroy segments of the wall. Vasculitis can involve vessels of any size and can affect any organ system. The clinical presentation varies according to the histologic type of inflammation, the size of the involved blood vessel segment, and the distribution of the involved vessels.

Many subtypes of vasculitis are recognized. This article focuses on the primary systemic vasculitides of childhood. The most common forms of systemic vasculitis in children are Henoch-Schoenlein purpura (HSP) and Kawasaki disease (KD). Other subtypes of primary childhood vasculitis are much rarer. Vasculitis can also occur secondary to another disease, and this should be ruled out. Diseases associated with secondary vasculitis include infection, malignancy, collagen vascular disease (eg, systemic lupus erythematosus, dermatomyositis), and drug hypersensitivity. See Differentials.

The image below depicts nodules in cutaneous polyarteritis nodosa (PAN), a systemic vasculitis characterized by necrotizing inflammatory lesions that affect medium-sized and small muscular arteries.

Nodules on sole of foot in cutaneous polyarteritis Nodules on sole of foot in cutaneous polyarteritis nodosa (PAN).

See Vasculitis: Case Presentations, a Critical Images slideshow, for more information on clinical, histologic, and radiographic imaging findings in various forms of vasculitis.

Next

Classification Guidelines

Practitioners may find it helpful to think of primary systemic vasculitides based on the predominant size of the involved vessels, as suggested by the Chapel Hill Classification.[1, 2] See the image below.

Preferred sites of vascular involvement by selecte Preferred sites of vascular involvement by selected vasculitides.

However, an overlap of vessel sizes affected within the diseases is noted, and the phenotype and pattern of organ involvement in vasculitis seems to be independent of vessel size. For example, Kawasaki disease is characterized by a mucocutaneous syndrome and coronary artery inflammation, whereas polyarteritis nodosa (PAN), another medium-vessel vasculitis, manifests with nodular skin lesions, neuropathy, and hypertension.

As such, the most recent classification of childhood vasculitides incorporates both vessel size and organ manifestations. This classification was proposed at a consensus conference in 2005 and was endorsed by Paediatric Rheumatology European Society (PRES) and the European League against Rheumatism (EULAR). These criteria represent a modification and adaptation of existing American College of Rheumatology and Chapel Hill criteria for vasculitis in adults.

Previous
Next

The EULAR and PRES Classification of Childhood Vasculitis

The predominantly large vessel vasculitis is Takayasu arteritis.

Predominantly medium-sized vessel vasculitis includes the following:

  • Childhood polyarteritis nodosa
  • Cutaneous polyarteritis
  • Kawasaki disease
  • Primary vasculitis of the CNS, angiography-positive primary angiitis of the CNS (PACNS)

Predominantly small vessel vasculitis is divided into granulomatous and nongranulomatous. Granulomatous includes the following:

  • Granulomatosis with polyangiitis (formerly known as Wegener granulomatosis)
  • Churg-Strauss syndrome

Nongranulomatous includes the following:

  • Microscopic polyangiitis
  • Henoch-Schönlein purpura
  • Isolated cutaneous leukocytoclastic vasculitis
  • Hypocomplementic urticarial vasculitis
  • Primary vasculitis of the CNS, angiography-negative, small vessel PACNS

Other vasculitides includes the following:

  • Behçet disease
  • Antiglomerular basement membrane (GBM) antibody disease
  • Vasculitis secondary to infection (including hepatitis B associated polyarteritis nodosa), malignancies, and drugs, including hypersensitivity vasculitis
  • Vasculitis associated with connective tissue diseases
  • Cogan syndrome
  • Unclassified
Previous
Next

Specific Classification Criteria

Large-vessel vasculitides

Note that the main large vessel vasculitis that affects children is Takayasu arteritis, and that temporal arteritis is not seen in the pediatric population. Takayasu arteritis is characterized by transmural inflammation and evidence of intramural giant cells. It involves the aorta and its major branches. Characteristic clinical features are caused by stenotic large vessels and subsequently decreased blood supply to the organ systems. Classically, children present with claudication, absent peripheral pulses, blood pressure abnormalities, strokes, and features of internal organ ischemia.

Classification criteria for Takayasu arteritis includes angiographic abnormalities (conventional, CT, or MRI) of the aorta or its main branches (mandatory criterion), plus at least one of the following features:

  • Decreased peripheral artery pulse and/or claudication of extremities
  • Blood pressure difference of more than 10 mm Hg
  • Bruits over aorta and/or its major branches
  • Hypertension (related to childhood normative data)

Medium-vessel vasculitides

The most common childhood medium-vessel vasculitis is Kawasaki disease. It is a necrotizing vasculitis that has a predilection for the coronary arteries. Classic features include prolonged fever, mucocutaneous changes and lymphadenopathy. Other manifestations may include irritability, arthritis, and abdominal pain.

Classification criteria for Kawasaki disease include a fever persisting for at least five days (mandatory criterion) plus 4 of the following 5 features:

  • Changes in peripheral extremities or perineal area
  • Polymorphous exanthema
  • Bilateral conjunctival injection
  • Changes of lips and oral cavity (injection of oral and pharyngeal mucosa)
  • Cervical lymphadenopathy

Childhood polyarteritis nodosa is a necrotizing vasculitis of medium-sized arteries and is recognized in distinct systemic and cutaneous forms.

Systemic polyarteritis nodosa involves all organ systems and the presentation widely varies.[3] Features include vasculitic skin lesions, hypertension, neuropathy, and myalgia. Note that renal involvement does not manifest as glomerulonephritis, as occurs with small-vessel disease. Unlike in adults, angiographic or biopsy evidence of vasculitis is required to make this diagnosis.

Classification criteria for childhood polyarteritis nodosa include a systemic illness characterized by the presence of either a biopsy finding that reveals small and mid-size artery necrotizing vasculitis or angiographic abnormalities (aneurysms or occlusions), plus at least 2 of the following:

  • Skin involvement (eg, livedo reticularis, tender subcutaneous nodules, other vasculitic lesions)
  • Myalgia or muscle tenderness
  • Systemic hypertension, relative to childhood normative data
  • Mononeuropathy or polyneuropathy
  • Abnormal urine analysis and/or impaired renal function (glomerular filtration rate of < 50% normal for age)
  • Testicular pain or tenderness
  • Signs or symptoms suggesting vasculitis of any other major organ system (GI, cardiac, pulmonary, CNS)

Cutaneous polyarteritis nodosa is characterized by the presence of subcutaneous nodular, painful, nonpurpuric lesions with or without livedo reticularis and absence of systemic involvement. However, more than half of patients also have myalgia, arthralgia, and nonerosive arthritis. Cutaneous polyarteritis nodosa has been associated with serological or microbiological evidence of streptococcal infection in 40% of patients.[3]

Childhood PACNS is defined by clinical evidence of a newly-acquired focal or diffuse neurologic deficit plus angiographic or histologic evidence of CNS vasculitis, in the absence of a systemic condition associated with these findings. Two clinically and radiologically distinct types of childhood PACNS are noted: large-medium vessel (angiography-positive) and small vessel (angiography-negative). These have different clinical presentations (see Primary CNS Vasculitis of Childhood).

Small-vessel vasculitides

Henoch-Schönlein purpura is the most common vasculitis in children, and is associated with immunoglobulin A (IgA) immune deposition in small vessels. Presenting features include palpable purpura, abdominal pain (which may be associated with GI hemorrhage and/or intussusception), arthritis, and evidence of glomerulonephritis (hematuria, proteinuria).

Classification criteria for Henoch-Schönlein purpura include palpable purpura (mandatory criterion) in the presence of at least one of following 4 features:

  • Diffuse abdominal pain
  • Any biopsy finding that reveals predominant lgA deposition
  • Arthritis or arthralgia (arthritis is acute in any joint)
  • Renal involvement (any hematuria, proteinuria)

Antineutrophil cytoplasmic antibody (ANCA) positive small-vessel vasculitides are also seen in the pediatric population. Granulomatosis with polyangiitis (GPA) (formerly known as Wegener granulomatosis) is a granulomatous vasculitis that most commonly involves the sinopulmonary system but can involve any organ system. Presenting features may include purpuric rash, recurrent sinusitis, epistaxis, shortness of breath, and/or hemoptysis from alveolar hemorrhage. It is also commonly associated with a necrotizing glomerulonephritis that may cause significant renal impairment.[4] Patients with Wegener granulomatosis have a positive ANCA finding in 90% of cases, most frequently in a cytoplasmic pattern (c-ANCA), with antibodies against proteinase 3 (anti-PR3).[5]

Classification criteria for GPA include 3 of the following 6 features:

  • Abnormal urinalysis findings (hematuria and/or significant proteinuria)
  • Granulomatous inflammation on biopsy (If a kidney biopsy is done it characteristically shows necrotizing pauci-immune glomerulonephritis.)
  • Nasal sinus inflammation
  • Subglottic, tracheal, or endobronchial stenosis
  • Abnormal chest radiography or CT findings
  • PR3 ANCA or c-ANCA staining

Microscopic polyangiitis (MPA) is a necrotizing vasculitis associated with glomerulonephritis and pulmonary capillaritis. Presenting features include purpuric rash, proteinuria and/or hematuria, hemoptysis, CNS involvement, and arthralgias.[6] MPA is associated with ANCA, most commonly with a perinuclear pattern (p-ANCA) and antibodies against myeloperoxidase (anti-MPO).

Churg-Strauss syndrome (CSS) is an eosinophilic granulomatous vasculitis characterized predominantly by pulmonary involvement. Patients typically have a previous history of asthma, allergic rhinitis, and/or sinusitis. A characteristic feature is the finding of nonfixed pulmonary infiltrates. Eosinophilic infiltration results in multiorgan involvement, including neuropathy and cardiovascular disease (pericarditis).[7] ANCA positivity is seen in approximately 40% of patients, usually with an “atypical” or “indeterminate” pattern.

Isolated cutaneous leukocytoclastic vasculitis can be either primary (rarely) or secondary to various medications, infections, or collagen vascular disease.

Hypocomplementemic urticarial vasculitis is a cutaneous vasculitis that may result from primary hypocomplementemia or as part of a disease associated with low complement levels (eg, systemic lupus erythematosus).

Other vasculitides

Behcet disease involves vessels of all sizes. The diagnosis is made clinically in patients with recurrent oral ulcers who also have recurrent genital ulcers, uveitis, various skin lesions, and/or a positive pathergy test.

Anti-GBM antibody disease/Goodpasture syndrome is a type of vasculitis caused by deposition of anti-GBM antibodies in small vessels of lungs and kidneys. Goodpasture syndrome clinically manifests with rapidly progressive glomerulonephritis and/or pulmonary hemorrhage (pulmonary renal syndrome).

Thrombophlebitis refers to inflammation of a vein associated with the formation of a blood clot. This may arise due to an interaction of endothelial injury, stasis of blood, and a hypercoagulable state. Risk factors include intravenous catheter placement, immobilization, malignancy, inherited prothrombotic condition (eg, factor V Leiden, antithrombin III deficiency), antiphospholipid antibody syndrome, and Behçet disease. One study found vascular involvement in 14% of patients with Behçet disease, most commonly manifesting as superficial vein thrombophlebitis or deep vein thrombosis.[8]

Previous
Next

Pathophysiology

Vessel inflammation occurs by various mechanisms in this heterogenous group of diseases. The histopathological pattern of inflammation is a characteristic feature of the vasculitis subtypes.

Lymphocytic/giant cell-mediated vasculitis

Takayasu arteritis and temporal arteritis (in adults) both involve large elastic arteries and share a similar histopathology. This form of vasculitis is T-cell dependent, and CD4+ T cells are the main players in the process. Dendritic cells within the arterial adventitia recruit and stimulate the CD4+ cells, which then activate the monocytes and macrophages that mediate oxidative injury of the vessel wall. Vascular lesions are characterized by a panarteritis with mononuclear infiltration of all layers of the arterial wall. Typically, activated T cells and macrophages are arranged in granulomas, and multinucleated giant cells are present. Often, the intimal layer is hyperplastic, leading to concentric occlusion of the lumen. Also, the end stage of giant-cell aortitis may be complicated by the formation and rupture of aneurysms.[9]

Necrotizing vasculitis

Kawasaki disease and polyarteritis nodosa are examples of necrotizing vasculitis. Possible etiologies in the case of Kawasaki disease include infectious agents and/or superantigen-mediated activation of lymphocytes. The inciting factors in polyarteritis nodosa are less well understood; however, in developing countries, it has been associated with hepatitis B or C. Pathologically, segmental transmural inflammation of muscular arteries is noted. Nodule (vascular narrowing) and aneurysm formation result from panmural fibrinoid necrosis. Note that aneurysmal dilatation of the arterial wall is a common feature of necrotizing vasculitis. Typically, immunofluorescence for immunoglobulin or complement deposition is negative.[10]

Antibody-mediated vasculitides

A review by Jennette and Falk discusses the scientific evidence showing that ANCA immunoglobulin Gs (IgGs) are involved in the pathogenesis of small vessel vasculitides such as GPA and MPA.[11]

ANCA antibodies are directed towards cytoplasmic proteins within neutrophils and monocytes (eg, PR3, MPO), which may also be expressed at the cell surface, particularly on stimulated cells. In vitro studies have shown that ANCA IgGs can directly activate neutrophils and monocytes by both Fc receptor engagement and direct Fab2 binding to antigen. These activated cells interact with endothelial cells via adhesion molecules and release inflammatory mediators, such as toxic granule enzymes and reactive oxygen metabolites that cause apoptosis and necrosis. In addition, anti-MPO IgG may activate MPO itself triggering an oxidative burst and resulting in severe endothelial damage. ANCA-activated neutrophils may release factors that activate the alternative complement pathway, which initiates an amplification loop that mediates the severe necrotizing inflammation of ANCA disease.[11]

In vivo studies also support this pathogenesis; for example, injection of mice with anti-MPO antibodies results in the development of necrotizing and crescentic glomerulonephritis and pulmonary capillaritis.[12]

A study that sought to assess clinical and B cell biomarkers to predict relapse after rituximab in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) using retreatment on clinical relapse strategy found that naïve B-lymphopenia may be a biomarker of disease activity in AAV.[13, 14]

Antibody deposition

Henoch-Schönlein purpura is generally characterized by the deposition of IgA antibodies in affected tissues. Histopathologically, the typical finding on skin biopsy is leukocytoclastic vasculitis, with perivascular accumulation of neutrophils and mononuclear cells. Immunofluorescence demonstrates IgA, C3, and fibrin in the walls of affected vessels, including the postcapillary venules within the dermis, and the endothelial and mesangial cells of the kidney. Elevated serum IgA and circulating IgA-containing immune complexes may be present in some patients. One study showed that galactose deficiency of O-linked glycans in the hinge region of IgA1 has been associated with Henoch-Schönlein purpura.[15]

In anti-GBM antibody disease, circulating antibodies bind to type IV collagen within the glomerular basement membrane. Immunofluorescence study of renal biopsies demonstrates linear deposition of IgG along the glomerular basement membrane. Pulmonary hemorrhage occurs when these antibodies have access to the alveolar basement membrane.

Previous
Next

Epidemiology

Frequency

United States

Henoch-Schönlein purpura is the most common vasculitis in childhood with an incidence of approximately 1 in 5000 children annually[16]

In North America, Kawasaki disease occurs in about approximately 20 per 100,000 children younger than 5 years.[17]

Granulomatosis with polyangiitis (formerly Wegener granulomatosis) is reported to occur in 0.03-3.2 per 100,000 children per year.[18]

The other vasculitides are quite rare in childhood.

International

In Japan, the incidence of Kawasaki disease is 188 per 100,000 children per year.[17]

Mortality/Morbidity

Morbidity and mortality in systemic vasculitides has been reviewed by Phillip and Luqmani; however, it is mainly based on adult data.[19]

In Kawasaki disease, acute mortality is 0.12% (mainly cardiac-related deaths). With appropriate treatment, the rate of coronary aneurysm development is approximately 2-4%.

Henoch-Schönlein purpura is usually a self-limited condition. The long-term prognosis relies mainly on the severity of renal involvement. The overall risk of end-stage renal disease is 1-3%, but this risk can increase to 20% if the patient presents with significant nephritis or nephrotic syndrome.[20] In adults with Henoch-Schönlein purpura, a higher rate of renal impairment is noted, and the 5-year survival rate is only approximately 75%.

Takaysu arteritis is associated with a 10-year survival rate of approximately 87%.

Polyarteritis nodosa and Churg-Strauss syndrome are associated with a 5-year survival rate of 75-80%.

Microscopic polyangiitis is associated with a 5 year survival rate of 45-75%.

Granulomatosis with polyangiitis (formerly Wegener granulomatosis) is associated with significant morbidity and mortality. Approximately 11% of patients require mechanical ventilation and/or require dialysis.[18] Survival is approximately 75% at 5 years in adults; survival data are not reported in pediatric patients.

Long-term data in childhood PACNS are lacking, but early recognition and treatment has been associated with good recovery.[21]

Race

The vasculitides are seen in patients of all races and ethnicities but some notable patterns of distribution are noted.

Kawasaki disease is most common in children of Japanese and other Asian descent

Henoch-Schönlein purpura is more common in Caucasians

Takayasu arteritis is more common in the Asian population

Behçet disease is more common in Turkey, the Middle East and eastern Asia

Sex

Henoch-Schönlein purpura has a male-to-female ratio of 2:1.

Kawasaki disease has a male-to-female ratio of 1.6:1.

Polyarteritis nodosa has a slight male preponderance.

Takayasu arteritis has a strong female preponderance.

Age

Henoch-Schönlein purpura has a peak age of onset at 3-10 years; 75% of patients are younger than 10 years.

Kawasaki disease has a mean age of onset 4.3 years; 80% of patients are younger than 5 years.[16]

Polyarteritis nodosa has a peak age of onset at 9-11 years.

Takayasu arteritis most commonly presents in the second and third decades of life; 20% are younger than 20 years.

Previous
 
 
Contributor Information and Disclosures
Author

Nadia Jennifer Chiara Luca, MD Fellow in Pediatric Rheumatology, University of Toronto Faculty of Medicine, Canada

Disclosure: Nothing to disclose.

Coauthor(s)

Susanne Maria Benseler, MD Pediatric Rheumatologist, Section Chief, Alberta Children's Hospital; Associate Professor, Department of Pediatrics, University of Calgary Faculty of Medicine, Canada

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Herbert S Diamond, MD Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, Phi Beta Kappa

Disclosure: Nothing to disclose.

Chief Editor

Lawrence K Jung, MD Chief, Division of Pediatric Rheumatology, Children's National Medical Center

Lawrence K Jung, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Rheumatology, Clinical Immunology Society, New York Academy of Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Barry L Myones, MD Co-Chair, Task Force on Pediatric Antiphospholipid Syndrome

Barry L Myones, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American College of Rheumatology, American Heart Association, American Society for Microbiology, Clinical Immunology Society, Texas Medical Association

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Christine Hom, MD, to the development and writing of this article.

References
  1. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb. 37(2):187-92. [Medline].

  2. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997 Nov 20. 337(21):1512-23. [Medline].

  3. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006 Jul. 65(7):936-41. [Medline]. [Full Text].

  4. Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004 Oct. 145(4):517-22. [Medline].

  5. Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum. 2007 Jun 15. 57(5):837-44. [Medline].

  6. Peco-Antic A, Bonaci-Nikolic B, Basta-Jovanovic G, et al. Childhood microscopic polyangiitis associated with MPO-ANCA. Pediatr Nephrol. 2006 Jan. 21(1):46-53. [Medline].

  7. Boyer D, Vargas SO, Slattery D, Rivera-Sanchez YM, Colin AA. Churg-Strauss syndrome in children: a clinical and pathologic review. Pediatrics. 2006 Sep. 118(3):e914-20. [Medline].

  8. Sarica-Kucukoglu R, Akdag-Kose A, KayabalI M, et al. Vascular involvement in Behçet's disease: a retrospective analysis of 2319 cases. Int J Dermatol. 2006 Aug. 45(8):919-21. [Medline].

  9. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med. 2003 Jul 10. 349(2):160-9. [Medline].

  10. Dedeoglu F, Sundel RP. Vasculitis in children. Rheum Dis Clin North Am. 2007 Aug. 33(3):555-83. [Medline].

  11. Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol. 2008 Jan. 20(1):55-60. [Medline].

  12. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002 Oct. 110(7):955-63. [Medline]. [Full Text].

  13. Md Yusof MY, Vital EM, Das S, Dass S, Arumugakani G, Savic S, et al. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. Ann Rheum Dis. 2015 Apr 8. [Medline].

  14. Janeczko LL. Naive B-Lymphopenia Possible Biomarker of Disease Activity in Vasculitis. http://www.medscape.com/viewarticle/843633. Available at http://www.medscape.com/viewarticle/843633. April 24, 2015; Accessed: July 1, 2015.

  15. Lau KK, Wyatt RJ, Moldoveanu Z, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol. 2007 Dec. 22(12):2067-72. [Medline].

  16. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002 Oct 19. 360(9341):1197-202. [Medline].

  17. Wu M-H, Nakamura Y, Burns JC, et al. State-of-the-art basic and clinical science of Kawasaki disease. Pediatric Health. 2008. 2:405-409.

  18. Cabral DA, Uribe AG, Benseler S, et al. Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. Arthritis Rheum. 2009 Nov. 60(11):3413-24. [Medline].

  19. Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. 2008 Sep-Oct. 26(5 Suppl 51):S94-104. [Medline].

  20. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005 Sep. 90(9):916-20. [Medline]. [Full Text].

  21. Elbers J, Benseler SM. Central nervous system vasculitis in children. Curr Opin Rheumatol. 2008 Jan. 20(1):47-54. [Medline].

  22. Reiff A. Ocular complications of childhood rheumatic diseases: nonuveitic inflammatory eye diseases. Curr Rheumatol Rep. 2009 Jul. 11(3):226-32. [Medline].

  23. Avcin T, Cimaz R, Rozman B. The Ped-APS Registry: the antiphospholipid syndrome in childhood. Lupus. 2009 Sep. 18(10):894-9. [Medline].

  24. Levine D, Akikusa J, Manson D, Silverman E, Schneider R. Chest CT findings in pediatric Wegener's granulomatosis. Pediatr Radiol. 2007 Jan. 37(1):57-62. [Medline].

  25. Kim YK, Lee KS, Chung MP, et al. Pulmonary involvement in Churg-Strauss syndrome: an analysis of CT, clinical, and pathologic findings. Eur Radiol. 2007 Dec. 17(12):3157-65. [Medline].

  26. Lauque D, Cadranel J, Lazor R, et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore). 2000 Jul. 79(4):222-33. [Medline].

  27. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995 Dec. 96(6):1057-61. [Medline].

  28. Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C. Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics. 2007 Nov. 120(5):1079-87. [Medline].

  29. Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC. Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP). Cochrane Database Syst Rev. 2009 Jul 8. CD005128. [Medline].

  30. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014 Mar. 121(3):785-96.e3. [Medline].

  31. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009 Mar. 68(3):310-7. [Medline].

  32. [Guideline] Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009 Mar. 68(3):318-23. [Medline].

  33. Guerry MJ, Brogan P, Bruce IN, D'Cruz DP, Harper L, Luqmani R. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012 Apr. 51(4):634-43. [Medline].

  34. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15. 363(3):221-32. [Medline].

  35. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15. 363(3):211-20. [Medline].

  36. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013 Aug 1. 369(5):417-27. [Medline].

  37. Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012 Mar. 71(3):327-33. [Medline].

  38. Faurschou M, Westman K, Rasmussen N, de Groot K, Flossmann O, Höglund P, et al. Long-term outcome of a clinical trial comparing methotrexate to cyclophosphamide for remission induction of early systemic ANCA-associated vasculitis. Arthritis Rheum. 2012 May 21. [Medline].

  39. Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, Grasland A, Zoulim A, LE Guen J. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol. 2012 Jan. 39(1):125-30. [Medline].

  40. Filocamo G, Buoncompagni A, Viola S, Loy A, Malattia C, Ravelli A, et al. Treatment of Takayasu's arteritis with tumor necrosis factor antagonists. J Pediatr. 2008 Sep. 153(3):432-4. [Medline].

  41. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007 Dec 15. 57(8):1487-95. [Medline].

  42. Lee BB, Laredo J, Neville R, Villavicencio JL. Endovascular management of takayasu arteritis: is it a durable option?. Vascular. 2009 May-Jun. 17(3):138-46. [Medline].

  43. Roediger FC, Orloff LA, Courey MS. Adult subglottic stenosis: management with laser incisions and mitomycin-C. Laryngoscope. 2008 Sep. 118(9):1542-6. [Medline].

  44. McCrindle BW. Kawasaki disease: a childhood disease with important consequences into adulthood. Circulation. 2009 Jul 7. 120(1):6-8. [Medline].

  45. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004 Oct 26. 110(17):2747-71. [Medline].

  46. Holve TJ, Patel A, Chau Q, Marks AR, Meadows A, Zaroff JG. Long-term cardiovascular outcomes in survivors of Kawasaki disease. Pediatrics. 2014 Feb. 133(2):e305-11. [Medline].

  47. Benseler SM, deVeber G, Hawkins C, et al. Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease. Arthritis Rheum. 2005 Jul. 52(7):2159-67. [Medline].

  48. Cantez S, Benseler SM. Childhood CNS vasculitis: a treatable cause of new neurological deficit in children. Nat Clin Pract Rheumatol. 2008 Sep. 4(9):460-1. [Medline].

  49. Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol. 2006 May. 17(5):1235-42. [Medline].

  50. McCrindle BW, McIntyre S, Kim C, Lin T, Adeli K. Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis?. J Pediatr. 2007 Sep. 151(3):244-8, 248.e1. [Medline].

 
Previous
Next
 
Preferred sites of vascular involvement by selected vasculitides.
Patient with Wegener granulomatosis and saddle-nose deformity.
Tender erythematous nodules in cutaneous polyarteritis nodosa (PAN).
Nodules on sole of foot in cutaneous polyarteritis nodosa (PAN).
Necrotic lesions of polyarteritis nodosa (PAN).
Chest radiography in Churg-Strauss syndrome (CSS) with pulmonary infiltrates.
CT of sinuses in a patient with Wegener granulomatosis (WG) showing erosion and loss of sinus walls.
CT chest in a patient with Churg-Strauss syndrome (CSS) showing multiple nodules.
Table 1. EUVAS disease categorization of ANCA-associated vasculitis
Category Definition
Localized Upper and/or lower respiratory tract disease without any other systemic



involvement or constitutional symptoms



Early



systemic



Any, without organ-threatening or life-threatening disease
Generalized Renal or other organ-threatening disease, serum creatinine >500



μmol/L (5.6 mg/dL)



Severe Renal or other vital organ failure, serum creatinine >500 μmol/L (5.6 mg/dL)
Refractory Progressive disease unresponsive to glucocorticoids and cyclophosphamide
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.